• Group revenue of US$247M, up 7% QoQ and 21% YoY
• Precision Medicine revenue of US$202M, up 9% QoQ and 30% YoY
• FDA alignment for ProstACT Global Phase 3 study of TLX591-Tx
• Patient enrollment nearing completion for BiPASS study
• Strategic collaboration with Regeneron for next-generation therapies

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) reported a strong Q2 2026 performance with group revenue of US$247 million, up 7% quarter-over-quarter and 21% year-over-year. Precision Medicine revenue was US$202 million, up 9% QoQ and 30% YoY. The company expects FY 2026 revenue and other income to exceed US$1 billion. The FDA confirmed safety data for ProstACT Global Phase 3 trial, enabling progression of Part 2 in the U.S. BiPASS Phase 3 study enrollment is nearing completion. Telix also announced a strategic collaboration with Regeneron for next-generation radiopharmaceutical therapies.

FY 2026 revenue expected to exceed US$1 billion, R&D expenditure guidance updated to US$230M-US$270M

Telix expects to achieve key regulatory, commercial, and clinical milestones, with continued investment in R&D to accelerate high-value programs.